SlideShare uma empresa Scribd logo
1 de 10
A STUDY ON PREVALENCE OF MICROVASCULAR COMPLICATIONS IN PATIENTS WITH NEWLY DETECTED DIABETES MELLITUS Dr. Tanoy Bose Laskar B, Bora w rejaMd, Dutta a Assam Medical College  Dibrugarh
Introduction: The Devastating Trio:  ◙ Neuropathy  ◙ Nephropathy  ◙ Retinopathy ↑ Glucose + ↓ Insulin: The driving forces Htn, Obesity, Dyslipidemia, Smoking: Accelerators Despite good long-term glycemic and BP control, diabetes remains a major cause of blindness, renal failure and amputations, all of which result in significant health care expenditure.
Objective: 	Determine the prevalence of microvascular complications in patients with newly diagnosed Diabetes Mellitus.
Inclusion Criteria: Age ≥ 12 years Newly detected DM diagnosed within preceding 6 mnths attending the Diabetic clinic Exclusion Criteria: ,[object Object]
Hepatic disorders, CKD, Acute infections, Trauma, Burns, AMI, Malignancy, Leprosy, Diphtheria, B1B6B12 deficiency
Conditions altering urinary albumin excretion e.g UTI, CHF, Drugs
Drugs altering OGTT e.g Steroids, Quinine, OCP, Salicylates etc.
Drugs causing Neuropathy, Nephropathy or Retinopathy.,[object Object]
Summary of Results: [n=90] 95.56% cases = Type 2 DM Mean age of detection of DM = 45.21y MC complication: Distal Sym Sensory Per Neuropathy ( 56.66%) f/b Nephropathy (36.66%) & Retinopathy (20%) MC isolated complication: Neuropathy (23.33%) Prevalence of Triopathy : 15.55% 90.9% were asymptomatic for nephropathy as were 70.58% for neuropathy.
Summary of Results continued:[n=90] Aged ≥ 50 years 78.12% of neuropathy cases 50% of nephropathy cases 37.5 % of retinopathy cases Comorbidities: [Out of 54 Htnsives ( 60%) ] 61.11% had neuropathy (vs 47.22% in normo) 38.88% had retinopathy (vs 11.11% in normo) 37.03% had nephropathy (vs 11.11% in normo) Comorbidities: [BMI] 84.6% had neuropathy among cases with BMI≥25 vs 43.47% among those with BMI ≤24.9.

Mais conteúdo relacionado

Mais procurados

inflammatory bowel disease in elderly
inflammatory  bowel disease in elderlyinflammatory  bowel disease in elderly
inflammatory bowel disease in elderlyDoha Rasheedy
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesNilesh Kucha
 
MS Disease modifying agents for multiple sclerosis
MS Disease modifying agents for multiple sclerosisMS Disease modifying agents for multiple sclerosis
MS Disease modifying agents for multiple sclerosisHossam Sayed
 
Management of Diabetic Nephropathy
Management of Diabetic NephropathyManagement of Diabetic Nephropathy
Management of Diabetic Nephropathydrsanjaymaitra
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Joel Topf
 
Diabetic Nephropathy Review
Diabetic Nephropathy ReviewDiabetic Nephropathy Review
Diabetic Nephropathy ReviewJAFAR ALSAID
 
Nephropathy
NephropathyNephropathy
Nephropathy39910152
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Tauhid Bhuiyan
 
Diabetic Nephropathy 1
Diabetic Nephropathy 1Diabetic Nephropathy 1
Diabetic Nephropathy 1mondy19
 
Myasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to managementMyasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to managementProfessor Yasser Metwally
 
Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Diabetic NephropathyUpendra Reddy
 
Epidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyEpidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyDINESH and SONALEE
 
Acromegaly : Acromegaly Symptoms and Treatment
Acromegaly : Acromegaly Symptoms and TreatmentAcromegaly : Acromegaly Symptoms and Treatment
Acromegaly : Acromegaly Symptoms and TreatmentDiabetologist
 
Idf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyIdf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyDiabetes for all
 
Castration resistant pprostate cancer.
Castration resistant pprostate cancer.Castration resistant pprostate cancer.
Castration resistant pprostate cancer.Imran Ansari
 

Mais procurados (20)

inflammatory bowel disease in elderly
inflammatory  bowel disease in elderlyinflammatory  bowel disease in elderly
inflammatory bowel disease in elderly
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
 
Popu research 22 morning ppt
Popu research 22 morning pptPopu research 22 morning ppt
Popu research 22 morning ppt
 
MS Disease modifying agents for multiple sclerosis
MS Disease modifying agents for multiple sclerosisMS Disease modifying agents for multiple sclerosis
MS Disease modifying agents for multiple sclerosis
 
Management of Diabetic Nephropathy
Management of Diabetic NephropathyManagement of Diabetic Nephropathy
Management of Diabetic Nephropathy
 
Diabetic Nephropathy 2009
Diabetic Nephropathy 2009Diabetic Nephropathy 2009
Diabetic Nephropathy 2009
 
Diabetic Nephropathy Review
Diabetic Nephropathy ReviewDiabetic Nephropathy Review
Diabetic Nephropathy Review
 
Nephropathy
NephropathyNephropathy
Nephropathy
 
DIABETIC NEPHROPATHY
DIABETIC NEPHROPATHYDIABETIC NEPHROPATHY
DIABETIC NEPHROPATHY
 
Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS)
 
Pitt figaro dkd
Pitt figaro dkdPitt figaro dkd
Pitt figaro dkd
 
Diabetic Nephropathy 1
Diabetic Nephropathy 1Diabetic Nephropathy 1
Diabetic Nephropathy 1
 
Myasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to managementMyasthenia Gravis..A quick guide to management
Myasthenia Gravis..A quick guide to management
 
Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Diabetic Nephropathy
 
Epidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathyEpidemiology of diabetic retinopathy
Epidemiology of diabetic retinopathy
 
Acromegaly : Acromegaly Symptoms and Treatment
Acromegaly : Acromegaly Symptoms and TreatmentAcromegaly : Acromegaly Symptoms and Treatment
Acromegaly : Acromegaly Symptoms and Treatment
 
Idf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathyIdf course module 3 diabetic nephropathy
Idf course module 3 diabetic nephropathy
 
Castration resistant pprostate cancer.
Castration resistant pprostate cancer.Castration resistant pprostate cancer.
Castration resistant pprostate cancer.
 
Relapse.Remitting.MS
Relapse.Remitting.MSRelapse.Remitting.MS
Relapse.Remitting.MS
 
Diabetic Nephropathy
Diabetic NephropathyDiabetic Nephropathy
Diabetic Nephropathy
 

Destaque

Complications of DM
Complications of DMComplications of DM
Complications of DMsnich
 
ACC/AHA 2009 Guidelines for STEMI & PCI
ACC/AHA 2009 Guidelines for STEMI & PCIACC/AHA 2009 Guidelines for STEMI & PCI
ACC/AHA 2009 Guidelines for STEMI & PCISun Yai-Cheng
 
STEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesSTEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesRommie Duckworth
 
Microvascular complications of diabetes pathophysiology
Microvascular complications of diabetes pathophysiologyMicrovascular complications of diabetes pathophysiology
Microvascular complications of diabetes pathophysiologyMWIZERWA JEAN-LUC
 
Diabetic Microvascular Complications
Diabetic  Microvascular  ComplicationsDiabetic  Microvascular  Complications
Diabetic Microvascular Complicationsdrmathewjohn
 

Destaque (6)

GLP-1 and Diabetes Mellitus
GLP-1 and Diabetes MellitusGLP-1 and Diabetes Mellitus
GLP-1 and Diabetes Mellitus
 
Complications of DM
Complications of DMComplications of DM
Complications of DM
 
ACC/AHA 2009 Guidelines for STEMI & PCI
ACC/AHA 2009 Guidelines for STEMI & PCIACC/AHA 2009 Guidelines for STEMI & PCI
ACC/AHA 2009 Guidelines for STEMI & PCI
 
STEMI and Acute Coronary Syndromes
STEMI and Acute Coronary SyndromesSTEMI and Acute Coronary Syndromes
STEMI and Acute Coronary Syndromes
 
Microvascular complications of diabetes pathophysiology
Microvascular complications of diabetes pathophysiologyMicrovascular complications of diabetes pathophysiology
Microvascular complications of diabetes pathophysiology
 
Diabetic Microvascular Complications
Diabetic  Microvascular  ComplicationsDiabetic  Microvascular  Complications
Diabetic Microvascular Complications
 

Semelhante a Microvascular In DM

Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Dr Surendra Khosya
 
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...rdaragnez
 
Minimal change nephrotic syndrome
Minimal change nephrotic syndromeMinimal change nephrotic syndrome
Minimal change nephrotic syndromeAmornpan Lertrit
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
CCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxCCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxAnshitaAggarwal7
 
Insulin Presentation-Gulu.pptx
Insulin Presentation-Gulu.pptxInsulin Presentation-Gulu.pptx
Insulin Presentation-Gulu.pptxDeriqueJoshua2
 
Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Dr Vivek Baliga
 
Membranous Nephropathy
Membranous NephropathyMembranous Nephropathy
Membranous Nephropathyedwinchowyw
 
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...hivlifeinfo
 
Renal cell carcinoma: clinical feature
Renal cell carcinoma: clinical featureRenal cell carcinoma: clinical feature
Renal cell carcinoma: clinical featureDr. Sumit KUMAR
 
Hb a1c goals
Hb a1c goalsHb a1c goals
Hb a1c goalsDaniel Wu
 
ueda2012 unmet needs in diabetes management-d.mgahed
ueda2012 unmet needs in diabetes management-d.mgahedueda2012 unmet needs in diabetes management-d.mgahed
ueda2012 unmet needs in diabetes management-d.mgahedueda2015
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...nephro mih
 
The relationship between gastrin hormone level and microalbumin urea in patie...
The relationship between gastrin hormone level and microalbumin urea in patie...The relationship between gastrin hormone level and microalbumin urea in patie...
The relationship between gastrin hormone level and microalbumin urea in patie...Alexander Decker
 
ueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahedueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahedueda2015
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabeticsMahmoud Yossof
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesUyen Nguyen
 

Semelhante a Microvascular In DM (20)

Type 2 DM and CKD
Type 2 DM and CKDType 2 DM and CKD
Type 2 DM and CKD
 
Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD) Marchiafava–Bignami disease (MBD)
Marchiafava–Bignami disease (MBD)
 
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
Simposio ALAD Avances en la prevención y el tratamiento de la diabetes tipo 2...
 
Minimal change nephrotic syndrome
Minimal change nephrotic syndromeMinimal change nephrotic syndrome
Minimal change nephrotic syndrome
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
CCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptxCCO_CLD_in_T2D_Downloadable_1.pptx
CCO_CLD_in_T2D_Downloadable_1.pptx
 
DM Lessons and Guidance
DM Lessons and GuidanceDM Lessons and Guidance
DM Lessons and Guidance
 
Insulin Presentation-Gulu.pptx
Insulin Presentation-Gulu.pptxInsulin Presentation-Gulu.pptx
Insulin Presentation-Gulu.pptx
 
Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?Management of coronary disease in diabetes - Is it different?
Management of coronary disease in diabetes - Is it different?
 
Membranous Nephropathy
Membranous NephropathyMembranous Nephropathy
Membranous Nephropathy
 
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
Slides to Guide Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do an...
 
Renal cell carcinoma: clinical feature
Renal cell carcinoma: clinical featureRenal cell carcinoma: clinical feature
Renal cell carcinoma: clinical feature
 
Hb a1c goals
Hb a1c goalsHb a1c goals
Hb a1c goals
 
ueda2012 unmet needs in diabetes management-d.mgahed
ueda2012 unmet needs in diabetes management-d.mgahedueda2012 unmet needs in diabetes management-d.mgahed
ueda2012 unmet needs in diabetes management-d.mgahed
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
 
The relationship between gastrin hormone level and microalbumin urea in patie...
The relationship between gastrin hormone level and microalbumin urea in patie...The relationship between gastrin hormone level and microalbumin urea in patie...
The relationship between gastrin hormone level and microalbumin urea in patie...
 
ueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahedueda2012 metabolic memory-d.mgahed
ueda2012 metabolic memory-d.mgahed
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabetics
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular Outcomes
 
Nodat
NodatNodat
Nodat
 

Mais de drtanoybose

Case Presentation On Respiratory Medicine
Case Presentation On Respiratory MedicineCase Presentation On Respiratory Medicine
Case Presentation On Respiratory Medicinedrtanoybose
 
Malaria Journal Bose T
Malaria Journal Bose TMalaria Journal Bose T
Malaria Journal Bose Tdrtanoybose
 
Microalbuminuria Bose T
Microalbuminuria  Bose TMicroalbuminuria  Bose T
Microalbuminuria Bose Tdrtanoybose
 
Presentation On Complete Hemogram
Presentation On Complete HemogramPresentation On Complete Hemogram
Presentation On Complete Hemogramdrtanoybose
 
Recent Rx Lymphoma
Recent Rx LymphomaRecent Rx Lymphoma
Recent Rx Lymphomadrtanoybose
 
A COMPARATIVE STUDY ON EFFICACY AND ADVERSE EFFECTS OF ANTIMALARIAL...
A  COMPARATIVE  STUDY  ON  EFFICACY   AND  ADVERSE  EFFECTS  OF  ANTIMALARIAL...A  COMPARATIVE  STUDY  ON  EFFICACY   AND  ADVERSE  EFFECTS  OF  ANTIMALARIAL...
A COMPARATIVE STUDY ON EFFICACY AND ADVERSE EFFECTS OF ANTIMALARIAL...drtanoybose
 
Albuminuria Dr T Bose
Albuminuria Dr T BoseAlbuminuria Dr T Bose
Albuminuria Dr T Bosedrtanoybose
 
Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)drtanoybose
 

Mais de drtanoybose (10)

Case Presentation On Respiratory Medicine
Case Presentation On Respiratory MedicineCase Presentation On Respiratory Medicine
Case Presentation On Respiratory Medicine
 
Malaria Journal Bose T
Malaria Journal Bose TMalaria Journal Bose T
Malaria Journal Bose T
 
Microalbuminuria Bose T
Microalbuminuria  Bose TMicroalbuminuria  Bose T
Microalbuminuria Bose T
 
Neuro HIVTanoy
Neuro HIVTanoyNeuro HIVTanoy
Neuro HIVTanoy
 
Presentation On Complete Hemogram
Presentation On Complete HemogramPresentation On Complete Hemogram
Presentation On Complete Hemogram
 
Recent Rx Lymphoma
Recent Rx LymphomaRecent Rx Lymphoma
Recent Rx Lymphoma
 
Telmisartan
TelmisartanTelmisartan
Telmisartan
 
A COMPARATIVE STUDY ON EFFICACY AND ADVERSE EFFECTS OF ANTIMALARIAL...
A  COMPARATIVE  STUDY  ON  EFFICACY   AND  ADVERSE  EFFECTS  OF  ANTIMALARIAL...A  COMPARATIVE  STUDY  ON  EFFICACY   AND  ADVERSE  EFFECTS  OF  ANTIMALARIAL...
A COMPARATIVE STUDY ON EFFICACY AND ADVERSE EFFECTS OF ANTIMALARIAL...
 
Albuminuria Dr T Bose
Albuminuria Dr T BoseAlbuminuria Dr T Bose
Albuminuria Dr T Bose
 
Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)Template For Poster Presentation (Tysa)
Template For Poster Presentation (Tysa)
 

Microvascular In DM

  • 1. A STUDY ON PREVALENCE OF MICROVASCULAR COMPLICATIONS IN PATIENTS WITH NEWLY DETECTED DIABETES MELLITUS Dr. Tanoy Bose Laskar B, Bora w rejaMd, Dutta a Assam Medical College Dibrugarh
  • 2. Introduction: The Devastating Trio: ◙ Neuropathy ◙ Nephropathy ◙ Retinopathy ↑ Glucose + ↓ Insulin: The driving forces Htn, Obesity, Dyslipidemia, Smoking: Accelerators Despite good long-term glycemic and BP control, diabetes remains a major cause of blindness, renal failure and amputations, all of which result in significant health care expenditure.
  • 3. Objective: Determine the prevalence of microvascular complications in patients with newly diagnosed Diabetes Mellitus.
  • 4.
  • 5. Hepatic disorders, CKD, Acute infections, Trauma, Burns, AMI, Malignancy, Leprosy, Diphtheria, B1B6B12 deficiency
  • 6. Conditions altering urinary albumin excretion e.g UTI, CHF, Drugs
  • 7. Drugs altering OGTT e.g Steroids, Quinine, OCP, Salicylates etc.
  • 8.
  • 9. Summary of Results: [n=90] 95.56% cases = Type 2 DM Mean age of detection of DM = 45.21y MC complication: Distal Sym Sensory Per Neuropathy ( 56.66%) f/b Nephropathy (36.66%) & Retinopathy (20%) MC isolated complication: Neuropathy (23.33%) Prevalence of Triopathy : 15.55% 90.9% were asymptomatic for nephropathy as were 70.58% for neuropathy.
  • 10. Summary of Results continued:[n=90] Aged ≥ 50 years 78.12% of neuropathy cases 50% of nephropathy cases 37.5 % of retinopathy cases Comorbidities: [Out of 54 Htnsives ( 60%) ] 61.11% had neuropathy (vs 47.22% in normo) 38.88% had retinopathy (vs 11.11% in normo) 37.03% had nephropathy (vs 11.11% in normo) Comorbidities: [BMI] 84.6% had neuropathy among cases with BMI≥25 vs 43.47% among those with BMI ≤24.9.
  • 11. Conclusions: Prevalence of microvascular complications in newly detected DM is significantly alarming. Distal symmetrical sensory neuropathy is the most prevalent complication both in combination as well as in isolation. Increasing age, Hypertension and higher BMI contributes to the prevalence of microvascular complications significantly.
  • 12. Take home message: Almost half of the battle is lost to the microvascular complications when Type 2 DM is diagnosed for the first time. Early detection, risk stratification and addressing the co morbidities remain the mainstay of controlling diabetic microvasculopathy and related morbidities.